Combination of chemo- and biocatalysis: Conversion of biomethane to methanol and formic acid

In the present day, methanol is mainly produced from methane via reforming processes, but research focuses on alternative production routes. Herein, we present a chemo-/biocatalytic oxidation cascade as a novel process to currently available methods. Starting from synthetic biogas, in the first step methane was oxidized to formaldehyde over a mesoporous VOx/SBA-15 catalyst. In the second step, the produced formaldehyde was disproportionated enzymatically towards methanol and formic acid in equimolar ratio by formaldehyde dismutase (FDM) obtained from Pseudomonas putida. Two processing routes were demonstrated: (a) batch wise operation using free formaldehyde dismutase after accumulating formaldehyde from the first step and (b) continuous operation with immobilized enzymes. Remarkably, the chemo-/biocatalytic oxidation cascades generate methanol in much higher productivity compared to methane monooxygenase (MMO) which, however, directly converts methane. Moreover, production steps for the generation of formic acid were reduced from four to two stages. © 2019 by the authors

Phosphorylation of phytochrome B inhibits light-induced signaling via accelerated dark reversion in Arabidopsis

The photoreceptor phytochrome B (phyB) interconverts between the biologically active Pfr (lmax = 730 nm) and inactive Pr (lmax = 660 nm) forms in a red/far-red–dependent fashion and regulates, as molecular switch, many aspects of lightdependent development in Arabidopsis thaliana. phyB signaling is launched by the biologically active Pfr conformer and mediated by specific protein–protein interactions between phyB Pfr and its downstream regulatory partners, whereas conversion of Pfr to Pr terminates signaling. Here, we provide evidence that phyB is phosphorylated in planta at Ser-86 located in the N-terminal domain of the photoreceptor. Analysis of phyB-9 transgenic plants expressing phospho-mimic and nonphosphorylatable phyB–yellow fluorescent protein (YFP) fusions demonstrated that phosphorylation of Ser-86 negatively regulates all physiological responses tested. The Ser86Asp and Ser86Ala substitutions do not affect stability, photoconversion, and spectral properties of the photoreceptor, but light-independent relaxation of the phyBSer86Asp Pfr into Pr, also termed dark reversion, is strongly enhanced both in vivo and in vitro. Faster dark reversion attenuates red light–induced nuclear import and interaction of phyBSer86Asp-YFP Pfr with the negative regulator PHYTOCHROME INTERACTING FACTOR3 compared with phyB–green fluorescent protein. These data suggest that accelerated inactivation of the photoreceptor phyB via phosphorylation of Ser-86 represents a new paradigm for modulating phytochrome-controlled signaling

Low resistance n-contact for UVC LEDs by a two-step plasma etching process

The impact of plasma etching on the formation of low-resistance n-contacts on the AlGaN:Si current spreading layer during the chip fabrication of ultraviolet light-emitting diodes (UV LEDs) emitting at 265 nm is investigated. A two-step plasma etching process with a first rapid etching using BCl3/Cl2 gas mixture and a second slow etching step using pure Cl2 gas has been developed. The etching sequence provides smooth mesa side-walls and an n-AlGaN surface with reduced surface damage. Ohmic n-contacts with a contact resistivity of 3.5 × 10−4 Ωcm2 are obtained on Si-doped Al0.65Ga0.35N layers and the operating voltages of the UVC LEDs were reduced by 2 V for a current of 20 mA.BMBF, 03ZZ0134B, Zwanzig20 - Advanced UV for Life - Verbundvorhaben: UV Power; TP2: Entwicklung von high-power UVB-LEDs um 300 nmBMBF, 03ZZ0134C, Zwanzig20 - Advanced UV for Life - Verbundvorhaben: UV Power; TP3: Epitaxieentwicklung für high-power UVC-LEDs um 260 n

Reducing Sitting Time After Stroke: A Phase II Safety and Feasibility Randomized Controlled Trial. ( Presented in part as a poster to the European Stroke Organization, April 17–19, 2015, Glasgow, United Kingdom; and Stroke 2015 (a combined conference of the Stroke Society of Australasia and Smartstrokes NSW), September 1–5, 2015, Melbourne, VIC, Australia.)

OBJECTIVE: To test the safety, feasibility, and effectiveness of reducing sitting time in stroke survivors. DESIGN: Randomized controlled trial with attention-matched controls and blinded assessments. SETTING: Community. PARTICIPANTS: Stroke survivors (N=35; 22 men; mean age, 66.9±12.7y). INTERVENTIONS: Four counseling sessions over 7 weeks with a message of sit less and move more (intervention group) or calcium for bone health (attention-matched control group). MAIN OUTCOME MEASURES: Measures included safety (adverse events, increases in pain, spasticity, or fatigue) and feasibility (adherence to trial protocol). Secondary measures included time spent sitting (including in prolonged bouts ≥30min), standing, and stepping as measured by the thigh-worn inclinometer (7d, 24h/d protocol) and time spent in physical activity of at least moderate intensity as measured by a triaxial accelerometer. The Multimedia Activity Recall for Children and Adults was used to describe changes in use of time. RESULTS: Thirty-three participants completed the full protocol. Four participants reported falls during the intervention period with no other adverse events. From a baseline average of 640.7±99.6min/d, daily sitting time reduced on average by 30±50.6min/d (95% confidence interval [CI], 5.8-54.6) in the intervention group and 40.4±92.5min/d in the control group (95% CI, 13.0-93.8). Participants in both groups also reduced their time spent in prolonged sitting bouts (≥30min) and increased time spent standing and stepping. CONCLUSIONS: Our protocol was both safe and feasible. Participants in both groups spent less time sitting and more time standing and stepping postintervention, but outcomes were not superior for intervention participants. Attention matching is desirable in clinical trials and may have contributed to the positive outcomes for control participants

The Acute Environment, Rather than T Cell Subset Pre-Commitment, Regulates Expression of the Human T Cell Cytokine Amphiregulin

Cytokine expression patterns of T cells can be regulated by pre-commitment to stable effector phenotypes, further modification of moderately stable phenotypes, and quantitative changes in cytokine production in response to acute signals. We showed previously that the epidermal growth factor family member Amphiregulin is expressed by T cell receptor-activated mouse CD4 T cells, particularly Th2 cells, and helps eliminate helminth infection. Here we report a detailed analysis of the regulation of Amphiregulin expression by human T cell subsets. Signaling through the T cell receptor induced Amphiregulin expression by most or all T cell subsets in human peripheral blood, including naive and memory CD4 and CD8 T cells, Th1 and Th2 in vitro T cell lines, and subsets of memory CD4 T cells expressing several different chemokine receptors and cytokines. In these different T cell types, Amphiregulin synthesis was inhibited by an antagonist of protein kinase A, a downstream component of the cAMP signaling pathway, and enhanced by ligands that increased cAMP or directly activated protein kinase A. Prostaglandin E2 and adenosine, natural ligands that stimulate adenylyl cyclase activity, also enhanced Amphiregulin synthesis while reducing synthesis of most other cytokines. Thus, in contrast to mouse T cells, Amphiregulin synthesis by human T cells is regulated more by acute signals than pre-commitment of T cells to a particular cytokine pattern. This may be appropriate for a cytokine more involved in repair than attack functions during most inflammatory responses

PP7 Is a Positive Regulator of Blue Light Signaling in Arabidopsis

The cryptochrome blue light photoreceptors mediate various photomorphogenic responses in plants, including hypocotyl elongation, cotyledon expansion, and control of flowering time. The molecular mechanism of cryptochrome function in Arabidopsis is becoming increasingly clear, with recent studies showing that both CRY1 and CRY2 are localized in the nucleus and that CRY2 is regulated by blue light–dependent phosphorylation. Despite these advances, no positive cryptochrome signaling component has been identified to date. Here, we demonstrate that a novel Ser/Thr protein phosphatase (AtPP7) with high sequence similarity to the Drosophila retinal degeneration C protein phosphatase acts as an intermediate in blue light signaling. Transgenic Arabidopsis seedlings with reduced AtPP7 expression levels exhibit loss of hypocotyl growth inhibition and display limited cotyledon expansion in response to blue light irradiation. These effects are as striking as those seen in hy4 mutant seedlings, which are deficient in CRY1. We further demonstrate that AtPP7 transcript levels are not rate limiting and that AtPP7 probably acts downstream of cryptochrome in the nucleus, ensuring signal flux through the pathway. Based on our findings and recent data regarding cryptochrome action, we propose that AtPP7 acts as a positive regulator of cryptochrome signaling in Arabidopsis

Guest Editorial: Montane rangelands in a changing world

No Abstract